Intersect ENT, Inc. (NASDAQ:XENT) COO Sells $353,125.00 in Stock
Intersect ENT, Inc. (NASDAQ:XENT) COO Richard E. Kaufman sold 12,500 shares of the business’s stock in a transaction dated Tuesday, July 25th. The stock was sold at an average price of $28.25, for a total value of $353,125.00. Following the transaction, the chief operating officer now owns 169,821 shares of the company’s stock, valued at $4,797,443.25. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.
Shares of Intersect ENT, Inc. (XENT) opened at 29.65 on Monday. The company’s market cap is $858.37 million. The stock’s 50 day moving average price is $27.55 and its 200-day moving average price is $20.21. Intersect ENT, Inc. has a 52 week low of $7.65 and a 52 week high of $29.90.
Intersect ENT (NASDAQ:XENT) last posted its earnings results on Tuesday, August 1st. The medical equipment provider reported ($0.08) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.11. Intersect ENT had a negative return on equity of 17.57% and a negative net margin of 22.94%. The firm had revenue of $24 million for the quarter, compared to the consensus estimate of $22.62 million. During the same quarter in the prior year, the business earned ($0.21) EPS. The business’s revenue for the quarter was up 24.4% on a year-over-year basis. Analysts expect that Intersect ENT, Inc. will post ($0.63) EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This article was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of international copyright laws. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/08/07/intersect-ent-inc-nasdaqxent-coo-sells-353125-00-in-stock-updated.html.
Several equities analysts have recently issued reports on XENT shares. Zacks Investment Research lowered Intersect ENT from a “hold” rating to a “sell” rating in a research report on Wednesday, July 5th. ValuEngine upgraded Intersect ENT from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. William Blair reiterated an “outperform” rating on shares of Intersect ENT in a report on Wednesday, May 10th. BidaskClub cut Intersect ENT from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 25th. Finally, Canaccord Genuity reiterated a “buy” rating and set a $32.00 price objective on shares of Intersect ENT in a report on Wednesday, August 2nd. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $23.13.
Several hedge funds have recently bought and sold shares of XENT. ClariVest Asset Management LLC bought a new stake in Intersect ENT during the first quarter valued at $148,000. Legal & General Group Plc increased its stake in Intersect ENT by 3.8% in the second quarter. Legal & General Group Plc now owns 6,939 shares of the medical equipment provider’s stock valued at $193,000 after buying an additional 255 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its stake in Intersect ENT by 109.1% in the first quarter. Cornerstone Capital Management Holdings LLC. now owns 11,500 shares of the medical equipment provider’s stock valued at $196,000 after buying an additional 6,000 shares during the last quarter. American International Group Inc. increased its stake in Intersect ENT by 7.1% in the first quarter. American International Group Inc. now owns 15,704 shares of the medical equipment provider’s stock valued at $269,000 after buying an additional 1,037 shares during the last quarter. Finally, Personal Capital Advisors Corp bought a new stake in Intersect ENT during the second quarter valued at $273,000. Institutional investors own 76.20% of the company’s stock.
Intersect ENT Company Profile
Intersect ENT, Inc is a commercial-stage drug-device company. The Company develops drugs for patients with ear, nose and throat (ENT) conditions. The Company has developed a drug releasing bioabsorbable implant technology that enables targeted and sustained release of therapeutic agents. This targeted drug delivery technology is designed to allow ENT physicians to manage patient care.
Receive News & Stock Ratings for Intersect ENT Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intersect ENT Inc. and related stocks with our FREE daily email newsletter.